Literature DB >> 25233931

Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.

Sharon E Murphy1, Sung-Shim L Park2, Elizabeth F Thompson3, Lynne R Wilkens4, Yesha Patel2, Daniel O Stram2, Loic Le Marchand4.   

Abstract

Nicotine metabolism influences smoking behavior and differences in metabolism probably contribute to ethnic variability in lung cancer risk. We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed. Nicotine and its metabolites were quantified in urine from African American (AA, n = 364), Native Hawaiian (NH, n = 311), White (n = 437), Latino (LA, n = 453) and Japanese American (JA, n = 674) smokers. Total nicotine equivalents, the sum of nicotine and six metabolites, and nicotine metabolism phenotypes were calculated. The relationship of UGT2B10 genotype to nicotine metabolic pathways was determined for each group; geometric means were computed and adjusted for age, sex, creatinine, and body mass index. Nicotine metabolism patterns were unique across the groups, C-oxidation was lowest in JA and NH (P < 0.0001), and N-glucuronidation lowest in AA (P < 0.0001). There was no difference in C-oxidation among Whites and AA and LA. Nicotine and cotinine glucuronide ratios were 2- and 3-fold lower in AA compared with Whites. Two UGT variants, a missense mutation (Asp67Tyr, rs61750900) and a splice variant (rs116294140) accounted for 33% of the variation in glucuronidation. In AA, the splice variant accounted for the majority of the reduced nicotine glucuronidation. UGT2B10 variant allele carriers had increased levels of C-oxidation (P = 0.0099). Our data indicate that the relative importance of nicotine metabolic pathways varies by ethnicity, and all pathways should be considered when characterizing the role of nicotine metabolism on smoking behavior and cancer risk.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25233931      PMCID: PMC4216060          DOI: 10.1093/carcin/bgu191

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  44 in total

1.  Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.

Authors:  Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Saito; Kazuma Kiyotani; Maxwell Afari Gyamfi; Masaharu Sakurai; Hirotoshi Dosaka-Akita; Yuichi Sawamura; Jun Yokota; Hideo Kunitoh; Tetsuya Kamataki
Journal:  Carcinogenesis       Date:  2004-08-12       Impact factor: 4.944

2.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Authors:  Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

Review 3.  Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen.

Authors:  John R Jalas; Stephen S Hecht; Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2005-02       Impact factor: 3.739

4.  Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes.

Authors:  Sharon E Murphy; Vytautas Raulinaitis; Kathryn M Brown
Journal:  Drug Metab Dispos       Date:  2005-04-28       Impact factor: 3.922

5.  Ethnic and racial differences in the smoking-related risk of lung cancer.

Authors:  Christopher A Haiman; Daniel O Stram; Lynne R Wilkens; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson; Loïc Le Marchand
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

6.  Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine.

Authors:  Hansen L Wong; Sharon E Murphy; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2005-01       Impact factor: 3.739

Review 7.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

8.  The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.

Authors:  Yesha M Patel; Daniel O Stram; Lynne R Wilkens; Sung-Shim L Park; Brian E Henderson; Loic Le Marchand; Christopher A Haiman; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-07       Impact factor: 4.254

9.  Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism.

Authors:  Kathryn M Brown; Linda B von Weymarn; Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2005-12       Impact factor: 3.739

10.  Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991.

Authors:  R S Caraballo; G A Giovino; T F Pechacek; P D Mowery; P A Richter; W J Strauss; D J Sharp; M P Eriksen; J L Pirkle; K R Maurer
Journal:  JAMA       Date:  1998-07-08       Impact factor: 56.272

View more
  86 in total

1.  Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Authors:  Eric C Donny; Rachel L Denlinger; Jennifer W Tidey; Joseph S Koopmeiners; Neal L Benowitz; Ryan G Vandrey; Mustafa al'Absi; Steven G Carmella; Paul M Cinciripini; Sarah S Dermody; David J Drobes; Stephen S Hecht; Joni Jensen; Tonya Lane; Chap T Le; F Joseph McClernon; Ivan D Montoya; Sharon E Murphy; Jason D Robinson; Maxine L Stitzer; Andrew A Strasser; Hilary Tindle; Dorothy K Hatsukami
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

2.  Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Authors:  Sharon E Murphy; Christopher J Sipe; Kwangsoo Choi; Leah M Raddatz; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-06       Impact factor: 4.254

3.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

4.  Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine.

Authors:  Lanqing Wang; John T Bernert; Neal L Benowitz; June Feng; Peyton Jacob; Ernest McGahee; Samuel P Caudill; Gerhard Scherer; Max Scherer; Nikola Pluym; Mira V Doig; Kirk Newland; Sharon E Murphy; Nicolas J Caron; Lane C Sander; Makiko Shimizu; Hiroshi Yamazaki; Sung Kim; Loralie J Langman; Jeanita S Pritchett; Lorna T Sniegoski; Yao Li; Benjamin C Blount; James L Pirkle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

5.  Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.

Authors:  Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen
Journal:  Addiction       Date:  2019-06-17       Impact factor: 6.526

6.  Nondaily Smokers' Changes in Cigarette Consumption With Very Low-Nicotine-Content Cigarettes: A Randomized Double-blind Clinical Trial.

Authors:  Saul Shiffman; Brenda F Kurland; Sarah M Scholl; Jason M Mao
Journal:  JAMA Psychiatry       Date:  2018-10-01       Impact factor: 21.596

7.  Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.

Authors:  Jian-Min Yuan; Irina Stepanov; Sharon E Murphy; Renwei Wang; Sharon Allen; Joni Jensen; Lori Strayer; Jennifer Adams-Haduch; Pramod Upadhyaya; Chap Le; Mindy S Kurzer; Heather H Nelson; Mimi C Yu; Dorothy Hatsukami; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-07

8.  Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine.

Authors:  Tracy T Smith; Laura E Rupprecht; Samantha N Cwalina; Matthew J Onimus; Sharon E Murphy; Eric C Donny; Alan F Sved
Journal:  Neuropsychopharmacology       Date:  2016-03-09       Impact factor: 7.853

9.  Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.

Authors:  Gang Chen; Shaman Luo; Shannon Kozlovich; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-09       Impact factor: 4.254

10.  Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine.

Authors:  Tracy T Smith; Joseph S Koopmeiners; Katelyn M Tessier; Esa M Davis; Cynthia A Conklin; Rachel L Denlinger-Apte; Tonya Lane; Sharon E Murphy; Jennifer W Tidey; Dorothy K Hatsukami; Eric C Donny
Journal:  Am J Prev Med       Date:  2019-10       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.